X
API Suppliers
US DMFs Filed
CEP/COS Certifications
JDMFs Filed
Other Certificates
Other Suppliers
0
USA (Orange Book)
Europe
Canada
Australia
South Africa
Uploaded Dossiers
U.S. Medicaid
Annual Reports
0
Details:
NMPA approved an bacterial DNA synthesis inhibitor antibiotic, metronidazole gel for the treatment of papulopustular rosacea, which uses Aptar Pharma’s Mezzo+ CS Airless dispensing solution for dermal drug delivery.
Lead Product(s): Metronidazole
Therapeutic Area: Dermatology Product Name: Undisclosed
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 11, 2024
Details:
Likmez(metronidazole) is a taste-masked liquid oral reformulation of metronidazole which effectively treats Clostridium difficile infection (CDI) in children by inhibiting protein synthesis by interacting with DNA leading cell death in susceptible organisms.
Lead Product(s): Metronidazole
Therapeutic Area: Infections and Infectious Diseases Product Name: Likmez
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 14, 2023
Details:
Likmez(metronidazole) is a taste-masked liquid oral reformulation of metronidazole which effectively treats Clostridium difficile infection (CDI) in children by inhibiting protein synthesis by interacting with DNA leading cell death in susceptible organisms.
Lead Product(s): Metronidazole
Therapeutic Area: Infections and Infectious Diseases Product Name: Likmez
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Saptalis pharm
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 25, 2023
Details:
Dapsone (metronidazole) is a vaginal gel, generic version of MetroGel-Vaginal by Bausch Health, and is indicated for the topical treatment of inflammatory lesions of rosacea.
Lead Product(s): Metronidazole
Therapeutic Area: Infections and Infectious Diseases Product Name: Dapsone
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 27, 2023
Details:
ATM-AVI (aztreonam-avibactam) is an investigational treatment for infections caused by Gram-negative bacteria with limited treatment options. It combines aztreonam, a monobactam β-lactam, with avibactam, a recent broad-spectrum β-lactamase inhibitor.
Lead Product(s): Aztreonam,Avibactam,Metronidazole
Therapeutic Area: Infections and Infectious Diseases Product Name: ATM-AVI
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 01, 2023
Details:
ATI-1501 (metronidazole) is a taste-masked liquid oral reformulation of metronidazole which effectively treats Clostridium difficile infection (CDI) in children by inhibiting protein synthesis by interacting with DNA leading cell death in susceptible organisms.
Lead Product(s): Metronidazole
Therapeutic Area: Infections and Infectious Diseases Product Name: ATI-1501
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 24, 2023
Details:
Bismuth subcitrate potassium and antibacterial agents (metronidazole and tetracycline hydrochloride) capsules in combination are indicated for treating H.pylori infection and duodenal ulcer disease to eradicate H. pylori.
Lead Product(s): Bismuth Potassium Citrate,Metronidazole,Tetracycline
Therapeutic Area: Infections and Infectious Diseases Product Name: Pylera-Generic
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 10, 2023
Details:
Metronidazole diffuses into the organism, inhibits protein synthesis by interacting with DNA, and causes a loss of helical DNA structure and strand breakage. Therefore, it causes cell death in susceptible organisms.
Lead Product(s): Metronidazole
Therapeutic Area: Infections and Infectious Diseases Product Name: Metronidazole-Generic
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 09, 2023
Details:
ATI-1501 (metronidazole) is a taste-masked liquid oral reformulation of metronidazole which effectively treats Clostridium difficile infection (CDI) in children by inhibiting protein synthesis by interacting with DNA leading cell death in susceptible organisms.
Lead Product(s): Metronidazole
Therapeutic Area: Infections and Infectious Diseases Product Name: ATI-1501
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 08, 2023
Details:
ATI-1501 (metronidazole) is a taste-masked liquid oral reformulation of metronidazole which effectively treats Clostridium difficile infection (CDI) in children by inhibiting protein synthesis by interacting with DNA leading cell death in susceptible organisms.
Lead Product(s): Metronidazole
Therapeutic Area: Infections and Infectious Diseases Product Name: ATI-1501
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 13, 2023
Details:
Pylera®, a 3-in-1 combination of antimicrobial products, is indicated for the treatment of patients with Helicobacter pylori infection suffering from gastro-duodenal ulcer disease.
Lead Product(s): Bismuth Potassium Citrate,Metronidazole,Tetracycline
Therapeutic Area: Infections and Infectious Diseases Product Name: Pylera
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: AbbVie Inc
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition July 05, 2022
Details:
Under the terms of the amended agreement, Saptalis will assume responsibility for development and commercialization of ATI-1501 in Europe and Latin America (collectively, the “Expanded Territories”).
Lead Product(s): Metronidazole
Therapeutic Area: Infections and Infectious Diseases Product Name: ATI-1501
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Saptalis pharm
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement February 08, 2022
Details:
According to IQVIATM sales data for the 12 month period ending November 2021, the MetroGelVaginal® Gel, 0.75% market2 achieved annual sales of approximately $60.4 million.
Lead Product(s): Metronidazole
Therapeutic Area: Infections and Infectious Diseases Product Name: MetroGel-Vaginal Gel
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 28, 2022
Details:
Metronidazole vaginal gel 0.75% is used to treat the symptoms of Bacterial Vaginosis. Metrogel Vaginal may be used alone or with other medications. It is a generic version of Metrogel-Vaginal.
Lead Product(s): Metronidazole
Therapeutic Area: Infections and Infectious Diseases Product Name: Metrogel-Vaginal
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 27, 2021
Details:
Aleor Dermaceuticals has received final approval from the US FDA for its Abbreviated New Drug Application for metronidazole gel USP, 1%. The ANDA is therapeutically equivalent to the reference listed drug product (RLD), Metrogel gel, 1%, of Galderma Laboratories LP.
Lead Product(s): Metronidazole
Therapeutic Area: Dermatology Product Name: Metrogel
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 06, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
